0
Aeglea BioTherapeutics, Inc. Banner Image

Aeglea BioTherapeutics, Inc.

  • Ticker AGLE
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Aeglea BioTherapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Austin, Texas
Aeglea is a clinical-stage biotechnology company that engineers next-generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead product candidate, for the treatment of Arginase 1 Deficiency which has received both Rare Pediatric Disease and Breakthrough Therapy DesignationMore. Aeglea has two programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline.
REPORT RATINGS
4.7 / 5.0 (64)

Aeglea BioTherapeutics, Inc. reports have an aggregate usefulness score of 4.7 based on 64 reviews.

Aeglea BioTherapeutics, Inc.

Most Recent Annual Report

Aeglea BioTherapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Aeglea BioTherapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!